Sienna Biopharmaceuticals, Inc. (SNNA) financial statements (2021 and earlier)
Company profile
| Business Address |
30699 RUSSELL RANCH ROAD, SUITE 140 WESTLAKE VILLAGE, CA 91362 |
| State of Incorp. | DE |
| Fiscal Year End | December 31 |
| SIC | 2834 - Pharmaceutical Preparations (benchmarking) |
| More info | Complete financial analysis Financial benchmarking |
Balance sheet (Statement of financial position) ($ in millions)
| 9/30/2019 TTM | 12/31/2018 | 12/31/2017 | |||
|---|---|---|---|---|---|
| ASSETS | |||||
| Current Assets | |||||
| Cash, cash equivalents, and short-term investments | 49 | 74 | |||
| Cash and cash equivalents | 49 | 74 | |||
| Restricted cash and investments | 0 | 0 | |||
| Other undisclosed current assets | 2 | 3 | |||
| Total current assets: | 50 | 77 | |||
| Noncurrent Assets | |||||
| Property, plant and equipment | 0 | 0 | |||
| Intangible assets, net (including goodwill) | 11 | 11 | |||
| Goodwill | 11 | 11 | |||
| Other undisclosed noncurrent assets | 46 | 48 | |||
| Total noncurrent assets: | 57 | 60 | |||
| TOTAL ASSETS: | 107 | 137 | |||
| LIABILITIES AND EQUITY | |||||
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 11 | 8 | |||
| Accounts payable | 3 | 2 | |||
| Accrued liabilities | 5 | 3 | |||
| Employee-related liabilities | 3 | 3 | |||
| Business combination, contingent consideration, liability | 14 | ||||
| Other undisclosed current liabilities | 0 | 0 | |||
| Total current liabilities: | 24 | 8 | |||
| Noncurrent Liabilities | |||||
| Long-term debt and lease obligation | 30 | ||||
| Long-term debt, excluding current maturities | 30 | ||||
| Liabilities, other than long-term debt | 26 | 34 | |||
| Deferred tax liabilities, net | ✕ | 11 | 11 | ||
| Business combination, contingent consideration, liability | 16 | 23 | |||
| Other undisclosed noncurrent liabilities | 0 | 4 | |||
| Total noncurrent liabilities: | 56 | 37 | |||
| Total liabilities: | 81 | 46 | |||
| Stockholders' equity | |||||
| Stockholders' equity attributable to parent | 27 | 91 | |||
| Common stock | 0 | ||||
| Additional paid in capital | 183 | 172 | |||
| Accumulated other comprehensive income | 3 | 5 | |||
| Accumulated deficit | (159) | (86) | |||
| Total stockholders' equity: | 27 | 91 | |||
| TOTAL LIABILITIES AND EQUITY: | 107 | 137 | |||
Income statement (P&L) ($ in millions)
| 9/30/2019 TTM | 12/31/2018 | 12/31/2017 | ||
|---|---|---|---|---|
| Operating expenses | (76) | (49) | ||
| Operating loss: | (76) | (49) | ||
| Nonoperating income (expense) | 3 | (2) | ||
| Loss from continuing operations before income taxes: | (73) | (51) | ||
| Income tax benefit | 0 | |||
| Net loss available to common stockholders, diluted: | (73) | (51) | ||
Comprehensive Income ($ in millions)
| 9/30/2019 TTM | 12/31/2018 | 12/31/2017 | ||
|---|---|---|---|---|
| Net loss: | (73) | (51) | ||
| Other comprehensive loss | (2) | |||
| Comprehensive loss: | (76) | (51) | ||
| Other undisclosed comprehensive income, net of tax, attributable to parent | 6 | |||
| Comprehensive loss, net of tax, attributable to parent: | (76) | (45) | ||
Statements sources
The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.